290 results on '"Bonelli, Michael"'
Search Results
2. Ex vivo imaging-based high content phenotyping of patients with rheumatoid arthritis
3. HDAC1 fine-tunes Th17 polarization in vivo to restrain tissue damage in fungal infections
4. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy
5. FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study
6. Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathy
7. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“)
8. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers
9. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
10. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
11. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
12. Mus musculus papillomavirus 1 is a key driver of skin cancer development upon immunosuppression
13. Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper
14. Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases.
15. Treg cells in health and autoimmune diseases: New insights from single cell analysis
16. Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis
17. Autoantibody development is associated with clinical severity of COVID-19: A cohort study
18. P160 Drug survival in SLE: real world data from the vienna lupus cohort
19. Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient—Addendum to the Genotype-Phenotype Puzzle
20. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes: JAKinibs suppress the interferon response in RA-FLSs
21. Treg cells in autoimmunity: from identification to Treg-based therapies
22. A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis
23. Amino acids fuel fibroblast‐like synoviocyte activation and arthritis by regulating chemokine expression and leukocyte migration
24. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
25. MicroRNA-146a governs fibroblast activation and joint pathology in arthritis
26. Amino Acids Fueling Fibroblast‐Like Synoviocyte Activation and Arthritis By Regulating Chemokine Expression and Leukocyte Migration.
27. The guanine nucleotide exchange factor Rin-like controls Tfh cell differentiation via CD28 signaling
28. Small extracellular vesicles are released ex vivo from platelets into serum and from residual blood cells into stored plasma
29. Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity
30. Helper T Cell Plasticity: Impact of Extrinsic and Intrinsic Signals on Transcriptomes and Epigenomes
31. Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach
32. Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination Stratagy
33. 9 - Signal transduction in immune cells
34. Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe
35. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers
36. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“)
37. Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study
38. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
39. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
40. Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency
41. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
42. The guanine nucleotide exchange factor Rin-like acts as a gatekeeper for T follicular helper cell differentiation via regulating CD28 signaling
43. Mo1389: NON-ALCOHOLIC FATTY LIVER DISEASE: DO NON-INVASIVE FIBROSIS SCORES STILL HAVE A ROLE IN PREDICTING EARLY STAGE HEPATIC FIBROSIS?
44. 02.06 Ccr6 modulates severity of arthritis in T cell dependent manner
45. 01.11 Resident non-classical monocytes are critically important for tissue destruction in arthritis
46. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis
47. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells
48. TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation
49. Neuropsychiatric Systemic Lupus Erythematosus: A Remaining Challenge
50. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.